+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

IL-17 Inhibitors for Psoriasis Market by Product (Brodalumab, Ixekizumab, Secukinumab), Indication (Plaque Psoriasis, Psoriatic Arthritis), Distribution Channel, End User, Therapeutic Regimen, Dosing Frequency, Patient Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6117643
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Psoriasis represents a chronic immune-mediated dermatological condition that affects millions of individuals globally, imposing not only a significant clinical burden but also profound psychosocial and economic impacts. The introduction of IL-17 inhibitors has marked a pivotal shift in therapeutic approaches, targeting key proinflammatory pathways to achieve superior efficacy and sustained remission compared to earlier biologic classes. By neutralizing specific cytokines central to the pathogenesis of psoriasis, these agents have redefined treatment expectations and elevated standards of care.

As the pharmaceutical industry contends with evolving patient needs and regulatory landscapes, IL-17 inhibitors such as brodalumab, ixekizumab, and secukinumab have emerged at the forefront of innovation. Their robust clinical profiles and ability to deliver rapid skin clearance have resonated with both clinicians and patients seeking durable outcomes. Concurrently, advances in biotechnology and drug delivery have enabled novel dosing regimens and formulations that further enhance adherence and convenience.

This executive summary synthesizes the critical dimensions shaping the IL-17 inhibitor segment, offering a concise yet comprehensive entry point into the market’s current state. It examines transformative shifts, regulatory influences, segmentation nuances, regional drivers, key corporate strategies, and methodological rigor. By integrating these perspectives, stakeholders will gain a clear understanding of emerging opportunities and challenges, ensuring informed decisions as the psoriasis treatment landscape continues to evolve.

Transformative Evolution of Psoriasis Treatment Landscape Driven by IL-17 Inhibitor Breakthroughs and Shifting Therapeutic Paradigms Fueling Patient Centricity

The landscape of psoriasis treatment has undergone transformative shifts over recent years, driven primarily by the advent of IL-17 inhibitors that have set new benchmarks in clinical efficacy. Through targeting the interleukin-17 cytokine, these therapies have introduced a level of precision that mitigates systemic inflammation while minimizing off-target effects. This mechanistic specificity has laid the groundwork for higher response rates and longer remission periods, reshaping therapeutic paradigms and patient expectations.

In parallel, the industry has witnessed an acceleration of innovation cycles, with pharmaceutical companies intensifying research on next-generation molecules and biosimilars to capture incremental value. Collaborations between biotech firms and larger manufacturers have become increasingly strategic, seeking to combine agility in early-stage development with the extensive commercialization capabilities of established players.

Furthermore, the integration of digital health platforms and remote monitoring tools is enhancing real-world evidence collection, enabling tailored treatment adjustments and improved patient adherence. As patient centricity gains prominence, value-based reimbursement models are emerging, incentivizing outcomes over volume and fostering a more sustainable ecosystem. Collectively, these shifts underscore the dynamic nature of the IL-17 inhibitor domain, where scientific breakthroughs and commercial strategies converge to elevate standards of care.

Assessing the Cumulative Impact of Recent United States Tariffs Enacted in 2025 on IL-17 Inhibitor Accessibility Supply and Pricing Strategies

The implementation of new United States tariff measures in 2025 has exerted a multifaceted impact on the accessibility and pricing structures of IL-17 inhibitors. On one hand, increased import costs for raw materials have challenged manufacturers to optimize supply chain efficiencies and absorb financial pressures without compromising on manufacturing excellence. As a result, procurement and distribution strategies have been recalibrated to mitigate cost escalation and preserve market competitiveness.

Meanwhile, healthcare providers and payers have responded with intensified negotiations around formulary inclusion and reimbursement terms. Negotiators are leveraging pharmacoeconomic data and real-world outcomes to justify value-based contracting arrangements that align long-term patient benefits with cost containment imperatives. This shift has catalyzed a broader dialogue around sustainable pricing frameworks that reward innovation while ensuring equitable access for diverse patient populations.

In parallel, some manufacturers have explored localized production partnerships and toll manufacturing agreements to circumvent tariff barriers, thereby stabilizing supply reliability. These strategic adaptations underscore the importance of regulatory agility and commercial resilience in an era of heightened trade tensions. Ultimately, the cumulative effect of the 2025 tariffs has spurred industry stakeholders to pursue more integrated and cost-effective approaches to delivering IL-17 inhibitor therapies.

Unveiling Critical Segmentation Insights on Product Indications Therapeutic Regimens Dosing Frequencies and Distribution Dynamics Driving IL-17 Inhibitor Use

A granular examination of market segmentation reveals diverse demand dynamics that vary according to product, indication, distribution channel, end user, therapeutic regimen, dosing frequency, and patient type. In terms of product differentiation, brodalumab distinguishes itself through its receptor antagonism mechanism, whereas ixekizumab and secukinumab offer distinct antibody profiles that influence onset of action and dosing schedules. When focusing on indications, plaque psoriasis continues to constitute the primary use case, while growing adoption in psoriatic arthritis underscores the expanding therapeutic reach.

Analysis of distribution modalities highlights the pivotal roles of hospital pharmacies in acute care settings and the rapid growth of online pharmacies driven by digital prescription models. Retail pharmacies, both chain and independent, maintain critical patient touchpoints, offering accessibility and patient education services. End users span home care settings where self-administration protocols have elevated convenience, as well as hospitals and specialty clinics that deliver supervised biologic infusions and monitoring.

Therapeutic regimen considerations further differentiate monotherapy from combination therapy strategies, the latter often incorporating agents such as cyclosporine or methotrexate to enhance efficacy in refractory cases. Dosing frequency emerges as another key dimension; the choice between biweekly and monthly administration influences patient adherence and overall treatment satisfaction. Finally, patient type segmentation between adult and pediatric cohorts, including adolescent and child subsets, illuminates distinct safety and efficacy profiles that must be addressed in clinical development and commercial planning. Together, these segmentation insights furnish a nuanced view of how diverse patient needs and care settings shape the IL-17 inhibitor market.

Regional Dynamics across Americas Europe Middle East Africa and Asia Pacific Highlighting Market Drivers and Adoption Trends for IL-17 Therapies

Regional analysis illustrates that the Americas lead in early adoption of IL-17 inhibitors, benefiting from robust reimbursement frameworks and a mature biologics market infrastructure. Key markets in North America exhibit high penetration rates, supported by extensive clinical awareness programs and streamlined regulatory pathways. Conversely, Europe, the Middle East, and Africa present a more heterogeneous environment, where diverse healthcare funding models and varying levels of market access influence uptake. Western European nations, in particular, demonstrate strong demand backed by value-based healthcare initiatives, while certain emerging markets face budgetary constraints that slow broader adoption.

In the Asia-Pacific region, rapid economic development coupled with growing healthcare expenditure is fueling interest in advanced biologic therapies. Governments in key Asia-Pacific markets are investing in strengthening regulatory frameworks and local manufacturing capabilities to ensure timely patient access. Furthermore, patient advocacy groups and digital health platforms are playing an increasingly influential role, promoting awareness and facilitating education about IL-17 inhibitor benefits and administration protocols.

Across all regions, local pricing negotiations and health technology assessments remain critical determinants of market entry and expansion. Strategic partnerships with regional distributors and the customization of access programs are essential for navigating the complex mosaic of regional reimbursement policies and achieving sustainable growth.

Uncovering Strategic Initiatives Innovations and Competitive Positioning of Leading Pharmaceutical Companies in the IL-17 Inhibitor Market for Psoriasis

Leading pharmaceutical companies are pursuing differentiated strategies to secure competitive advantage in the IL-17 inhibitor space. Janssen has leveraged its deep expertise in large-molecule development to enrich its clinician engagement programs and expand its patient support services around secukinumab. By investing in real-world evidence studies, the company is reinforcing the therapy’s long-term safety profile and cost effectiveness.

Eli Lilly has augmented its commercialization approach for ixekizumab through strategic collaborations with specialty pharmacies and digital health partners, facilitating seamless patient onboarding and adherence monitoring. Emphasis on robust patient education platforms has enhanced confidence in self-injection techniques and expanded access in home care settings.

Smaller biotech entities have differentiated by focusing on niche indications and novel formulation technologies, forging alliances with larger firms to expedite clinical development and regulatory approval. These partnerships often include co-promotion agreements and shared risk-sharing models, enabling agile market entry without extensive capital investment.

Across the competitive landscape, companies are also prioritizing pipeline differentiation with next-generation candidates targeting IL-17F and dual cytokine blockade to address residual unmet needs. Such innovation demonstrates the ongoing commitment of industry leaders to refine therapeutic profiles and consolidate their positions in a rapidly evolving market.

Strategic Roadmap for Industry Stakeholders to Optimize IL-17 Inhibitor Development Commercialization and Patient Engagement through Data Driven Initiatives

Industry leaders should embrace a multifaceted roadmap that integrates rigorous clinical development with patient-centric commercialization tactics. First, optimizing pipeline portfolios through the exploration of dual-pathway inhibitors and periodic lifecycle management enhancements can sustain therapeutic differentiation. Coupled with adaptive clinical trial designs, this approach accelerates time-to-market while mitigating development risk.

Simultaneously, forging strategic alliances with specialty pharmacies and digital health providers will streamline patient access and adherence. Leveraging telemedicine platforms for remote monitoring and educational outreach can further enhance real-world effectiveness and patient satisfaction. In parallel, engaging payers through value demonstration initiatives that emphasize long-term health economic outcomes will facilitate favorable formulary positioning and reimbursement agreements.

In markets affected by tariff dynamics, exploring local manufacturing partnerships or toll processing arrangements can alleviate cost pressures and ensure a resilient supply chain. Additionally, tailoring market access programs to regional nuances-such as co-payment assistance in emerging economies-will broaden reach while preserving financial viability.

By aligning innovation pipelines with strategic commercialization frameworks and payer engagement, industry stakeholders can secure sustainable growth, optimize patient outcomes, and reinforce leadership in the competitive IL-17 inhibitor space.

Research Methodology Outlining Data Collection Analytical Framework and Validation Techniques Underpinning the IL-17 Inhibitor Psoriasis Market Study

This study employs a rigorous, multi-layered research methodology designed to ensure robustness and validity of findings. Primary research constitutes in-depth interviews with key opinion leaders, dermatologists, rheumatologists, and payers across major geographies, providing direct insights into clinical preferences, market access challenges, and evolving treatment paradigms. These qualitative inputs are complemented by a systematic review of peer-reviewed publications, regulatory filings, and clinical trial registries to substantiate therapeutic efficacy, safety profiles, and pipeline developments.

Secondary data collection involved the analysis of proprietary databases, government health agency reports, and industry white papers to capture historical trends and regulatory frameworks. All quantitative data points are triangulated using multiple sources to reconcile any discrepancies and enhance accuracy. The segmentation framework was constructed based on product, indication, distribution channel, end user, therapeutic regimen, dosing frequency, and patient type to reflect real-world market dynamics comprehensively.

Analytical techniques include SWOT assessment, Porter’s Five Forces evaluation, and scenario planning to explore potential market shifts. Economic and tariff impact analyses were conducted using sensitivity modeling to estimate cost implications under varied trade scenarios. Throughout, validation workshops with external stakeholders were held to corroborate findings and refine strategic recommendations. This methodological rigor underpins the credibility and actionable nature of the report’s insights.

Concluding Perspectives on IL-17 Inhibitors Shaping Future Psoriasis Treatment Paradigms and Industry Collaboration to Enhance Patient Outcomes

The evolution of IL-17 inhibitors represents a defining moment in the management of psoriasis and related conditions, marrying targeted immunology with patient-centered care strategies. As competitive dynamics intensify and regulatory landscapes shift, stakeholders must remain agile, leveraging both clinical evidence and commercial acumen to navigate emerging challenges. The convergence of innovative biologic therapies, value-based contracting, and digital health integration underscores the necessity of a holistic, forward-looking approach.

By synthesizing segmentation insights, regional nuances, and corporate strategies, this analysis equips decision-makers with a nuanced understanding of market forces. The industry’s trajectory will be shaped by ongoing scientific advancements, strategic partnerships, and evolving reimbursement frameworks. Maintaining a focus on measurable patient outcomes and sustainable business models will be paramount as the IL-17 inhibitor segment continues to expand its therapeutic impact.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Product
    • Brodalumab
    • Ixekizumab
    • Secukinumab
  • Indication
    • Plaque Psoriasis
    • Psoriatic Arthritis
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
      • Chain
      • Independent
  • End User
    • Home Care Settings
    • Hospitals
    • Specialty Clinics
  • Therapeutic Regimen
    • Combination Therapy
      • Cyclosporine
      • Methotrexate
    • Monotherapy
  • Dosing Frequency
    • Biweekly
    • Monthly
  • Patient Type
    • Adult
    • Pediatric
      • Adolescent
      • Child
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Novartis AG
  • Eli Lilly and Company
  • Bausch Health Companies Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing integration of real-world evidence in demonstrating long term safety and efficacy of IL-17 inhibitors
5.2. Emergence of next generation IL-17 inhibitors with improved dosing convenience and more targeted biology
5.3. Growing payer restrictions and step therapy protocols shaping IL-17 inhibitor market access dynamics
5.4. Expansion of patient support programs and digital tools to enhance adherence to IL-17 inhibitor treatments
5.5. Intensifying competition from dual cytokine inhibitors and pipeline therapies challenging IL-17 dominance
5.6. Regional variations in IL-17 inhibitor uptake driven by differing reimbursement and healthcare infrastructure
5.7. Surge in head to head clinical trials comparing IL-17 inhibitors against alternative biologic classes
5.8. Rising investment in biomarker driven patient stratification to optimize IL-17 inhibitor therapy outcomes
5.9. Impact of COVID-19 on prescribing patterns and monitoring practices for IL-17 inhibitors in psoriasis patients
5.10. Increasing focus on long term safety data to support labeling expansion and market penetration for IL-17 inhibitors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. IL-17 Inhibitors for Psoriasis Market, by Product
8.1. Introduction
8.2. Brodalumab
8.3. Ixekizumab
8.4. Secukinumab
9. IL-17 Inhibitors for Psoriasis Market, by Indication
9.1. Introduction
9.2. Plaque Psoriasis
9.3. Psoriatic Arthritis
10. IL-17 Inhibitors for Psoriasis Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.4.1. Chain
10.4.2. Independent
11. IL-17 Inhibitors for Psoriasis Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. IL-17 Inhibitors for Psoriasis Market, by Therapeutic Regimen
12.1. Introduction
12.2. Combination Therapy
12.2.1. Cyclosporine
12.2.2. Methotrexate
12.3. Monotherapy
13. IL-17 Inhibitors for Psoriasis Market, by Dosing Frequency
13.1. Introduction
13.2. Biweekly
13.3. Monthly
14. IL-17 Inhibitors for Psoriasis Market, by Patient Type
14.1. Introduction
14.2. Adult
14.3. Pediatric
14.3.1. Adolescent
14.3.2. Child
15. Americas IL-17 Inhibitors for Psoriasis Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa IL-17 Inhibitors for Psoriasis Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific IL-17 Inhibitors for Psoriasis Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novartis AG
18.3.2. Eli Lilly and Company
18.3.3. Bausch Health Companies Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. IL-17 INHIBITORS FOR PSORIASIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. IL-17 INHIBITORS FOR PSORIASIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. IL-17 INHIBITORS FOR PSORIASIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. IL-17 INHIBITORS FOR PSORIASIS MARKET: RESEARCHAI
FIGURE 30. IL-17 INHIBITORS FOR PSORIASIS MARKET: RESEARCHSTATISTICS
FIGURE 31. IL-17 INHIBITORS FOR PSORIASIS MARKET: RESEARCHCONTACTS
FIGURE 32. IL-17 INHIBITORS FOR PSORIASIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IL-17 INHIBITORS FOR PSORIASIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BIWEEKLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BIWEEKLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONTHLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONTHLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHILD, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHILD, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 119. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 120. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 121. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 126. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 127. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 130. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 131. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 132. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 133. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 134. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 135. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 136. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 137. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 138. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 139. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 140. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 141. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 142. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 143. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 146. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 147. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 150. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 151. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 152. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 153. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 154. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 155. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 156. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 157. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 158. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 241. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 242. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 243. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 248. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 249. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 252. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 253. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 254. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 255. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 256. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 257. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 258. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 259. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 260. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 261. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 262. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 263. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 264. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 265. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 268. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 269. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 272. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 273. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 274. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 275. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 276. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 277. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 278. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 279. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 280. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 301. ITALY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 302. ITALY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 303. ITALY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 3

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this IL-17 Inhibitors for Psoriasis market report include:
  • Novartis AG
  • Eli Lilly and Company
  • Bausch Health Companies Inc.